FY2025 EPS Estimate for Sanara MedTech Increased by Analyst

Sanara MedTech Inc. (NASDAQ:SMTI) – Equities research analysts at HC Wainwright upped their FY2025 earnings estimates for Sanara MedTech in a report issued on Monday, January 26th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of $0.20 for the year, up from their previous estimate of $0.19. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

Sanara MedTech (NASDAQ:SMTI) last announced its earnings results on Wednesday, November 12th. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.33. Sanara MedTech had a negative net margin of 36.79% and a negative return on equity of 21.33%. The company had revenue of $26.33 million during the quarter, compared to the consensus estimate of $26.63 million.

A number of other brokerages have also recently weighed in on SMTI. Zacks Research cut shares of Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a research note on Thursday. Finally, Wall Street Zen lowered Sanara MedTech from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $41.00.

Sanara MedTech Stock Down 2.3%

Shares of NASDAQ SMTI opened at $21.25 on Tuesday. Sanara MedTech has a 1 year low of $18.90 and a 1 year high of $37.91. The firm’s 50-day moving average is $22.84 and its 200-day moving average is $27.28. The company has a current ratio of 1.80, a quick ratio of 1.60 and a debt-to-equity ratio of 7.34. The firm has a market capitalization of $189.13 million, a PE ratio of -5.04 and a beta of 1.06.

Hedge Funds Weigh In On Sanara MedTech

Several hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its stake in shares of Sanara MedTech by 351.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock worth $48,000 after buying an additional 1,171 shares during the last quarter. Lazard Asset Management LLC boosted its position in Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock valued at $89,000 after purchasing an additional 3,155 shares during the last quarter. Bank of America Corp DE grew its stake in Sanara MedTech by 44.1% in the third quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock valued at $101,000 after purchasing an additional 973 shares in the last quarter. Rhumbline Advisers increased its position in shares of Sanara MedTech by 14.9% during the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock worth $115,000 after purchasing an additional 483 shares during the last quarter. Finally, Salem Investment Counselors Inc. raised its stake in shares of Sanara MedTech by 25.0% during the 4th quarter. Salem Investment Counselors Inc. now owns 10,897 shares of the company’s stock worth $254,000 after purchasing an additional 2,182 shares in the last quarter. 8.10% of the stock is owned by institutional investors.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.